Robert Harte

Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial

Rob Glynne‐Jones, David Sebag‐Montefiore, Helen Meadows et al. · The Lancet Oncology · 2017 · 178 citations · Full text

Pharmacokinetic Evaluation of N-[2-(Dimethylamino)Ethyl]Acridine-4-Carboxamide in Patients by Positron Emission Tomography

Azeem Saleem, Robert Harte, Julian C. Matthews et al. · Journal of Clinical Oncology · 2001 · 80 citations

Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: A feasibility study

Steven R. Meikle, Julian C. Matthews, Cathryn Brock et al. · Cancer Chemotherapy and Pharmacology · 1998 · 56 citations

Positron Emission Tomography, Oncology, Health Sciences +15

Tumor, Normal Tissue, and Plasma Pharmacokinetic Studies of Fluorouracil Biomodulation With<i>N</i>-Phosphonacetyl-<scp>l</scp>-aspartate, Folinic Acid, and Interferon Alfa

Robert Harte, Julian C. Matthews, S.M. O'Reilly et al. · Journal of Clinical Oncology · 1999 · 52 citations

ARISTOTLE: A phase III trial comparing concurrent capecitabine with capecitabine and irinotecan (Ir) chemoradiation as preoperative treatment for MRI-defined locally advanced rectal cancer (LARC).

David Sebag‐Montefiore, Richard Adams, Simon Gollins et al. · Journal of Clinical Oncology · 2020 · 22 citations

Radiation Medicine, Surgical Oncology, Concurrent Capecitabine +14